Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open wounds. Signs and symptoms include fever, cough, chest pain, headache and anorexia. Risk factors include liver disease, diabetes, and thalassemia.

The Burkholderia Pseudomallei Infections (Melioidosis) pipeline drugs market research report provides a comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.

Melioidosis Pipeline Drugs Market Segmentation by Targets

The key targets in the Melioidosis pipeline drugs market are Beta Lactamase, DNA Gyrase, DNA Topoisomerase IV, Elongation Factor G, Enoyl [Acyl Carrier Protein] Reductase [NADH], Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, and Leucine tRNA Ligase Cytoplasmics.

Melioidosis Pipeline Drugs Market Analysis, by Targets

Melioidosis Pipeline Drugs Market Analysis, by Targets

For more insights on Melioidosis pipeline drugs targets, download a free report sample

Melioidosis Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions in the Melioidosis pipeline drugs market are Beta Lactamase Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Elongation Factor G Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, and Leucine tRNA Ligase Cytoplasmic Inhibitor.

Melioidosis Pipeline Drugs Market Analysis, by Mechanism of Actions

Melioidosis Pipeline Drugs Market Analysis, by Mechanism of Actions

For more insights on Melioidosis pipeline drugs mechanism of actions, download a free report sample

Melioidosis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Melioidosis pipeline drugs market are intravenous, oral, and muscular.

Melioidosis Pipeline Drugs Market Analysis, by Routes of Administration

Melioidosis Pipeline Drugs Market Analysis, by Routes of Administration

For more insights on Melioidosis pipeline drugs routes of administration, download a free report sample

Melioidosis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Melioidosis pipeline drugs market are small molecule, conjugate vaccine, synthetic peptide, and vaccine.

Melioidosis Pipeline Drugs Market Analysis, by Molecule Types

Melioidosis Pipeline Drugs Market Analysis, by Molecule Types

 For more insights on Melioidosis pipeline drugs molecule type, download a free report sample

Competitive Landscape

Some of the leading companies in the Melioidosis pipeline drugs market are Aceragen Inc, AN2 Therapeutics Inc, Bugworks Research Inc, Entasis Therapeutics Holdings Inc, and Soligenix Inc.

Competitive Landscape

Melioidosis Pipeline Drugs Market Overview

Key Targets Beta Lactamase, DNA Gyrase, DNA Topoisomerase IV, Elongation Factor G, Enoyl [Acyl Carrier Protein] Reductase [NADH], Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, and Leucine tRNA Ligase Cytoplasmics
Key Mechanism of Actions Beta Lactamase Inhibitor, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, Elongation Factor G Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, and Leucine tRNA Ligase Cytoplasmic Inhibitor
Key Routes of Administration Intravenous, Oral, and Muscular
Key Molecule Types Small Molecule, Conjugate Vaccine, Synthetic Peptide, and Vaccine
Leading Companies Aceragen Inc, AN2 Therapeutics Inc, Bugworks Research Inc, Entasis Therapeutics Holdings Inc, and Soligenix Inc

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Aceragen Inc
AN2 Therapeutics Inc
Bugworks Research Inc
Entasis Therapeutics Holdings Inc
Soligenix Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Burkholderia pseudomallei Infections (Melioidosis) – Overview

Burkholderia pseudomallei Infections (Melioidosis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Burkholderia pseudomallei Infections (Melioidosis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Burkholderia pseudomallei Infections (Melioidosis) – Companies Involved in Therapeutics Development

Aceragen Inc

AN2 Therapeutics Inc

Bugworks Research Inc

Entasis Therapeutics Holdings Inc

Soligenix Inc

Burkholderia pseudomallei Infections (Melioidosis) – Drug Profiles

(durlobactam sodium + sulbactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

BWC-0977 – Drug Profile

Product Description

Mechanism Of Action

History of Events

epetraborole – Drug Profile

Product Description

Mechanism Of Action

History of Events

fusidic acid – Drug Profile

Product Description

Mechanism Of Action

History of Events

melioidosis vaccine – Drug Profile

Product Description

Mechanism Of Action

POLB-003 – Drug Profile

Product Description

Mechanism Of Action

SGX-943 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Infectious Diseases – Drug Profile

Product Description

Mechanism Of Action

Burkholderia pseudomallei Infections (Melioidosis) – Dormant Projects

Burkholderia pseudomallei Infections (Melioidosis) – Discontinued Products

Burkholderia pseudomallei Infections (Melioidosis) – Product Development Milestones

Featured News & Press Releases

Jun 15, 2022: Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis

May 18, 2022: Poolbeg Pharma : European Melioidosis Congress

Jan 05, 2022: Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for development of ACG-701 as medical countermeasure against melioidosis

Apr 26, 2021: Bugworks secures funding from US Government’s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats

Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference

May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis

Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Aceragen Inc, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by AN2 Therapeutics Inc, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Bugworks Research Inc, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Entasis Therapeutics Holdings Inc, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Pipeline by Soligenix Inc, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Dormant Projects, 2022

Burkholderia pseudomallei Infections (Melioidosis) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Burkholderia Pseudomallei Infections (Melioidosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.